Xcovery wins FDA approval for ALK inhibitor in NSCLC

[cafead]

via The FDA on Wednesday approved Xcovery's Ensacove (ensartinib) to treat patients with ALK-positive, locally advanced or metastatic non–small-cell lung cancer (NSCLC) who have not previously received an ALK inhibitor.

article source